• FK866 (APO866) Workflows for NAD Cancer Research

  2026-09-15

  FK866 (APO866) enables controlled NAMPT inhibition for NAD-depletion studies, AML models, and biomarker-led combination experiments. This guide connects practical assay design with emerging evidence that RAS/PI3K pathway status can influence responses to FK866 plus PARP inhibition.

• Moesin and Endothelial Injury in Sepsis

  2026-09-15

  The reference study identifies circulating moesin as a candidate biomarker associated with sepsis severity and endothelial barrier disruption. By combining patient measurements, murine LPS and cecal ligation and puncture models, and HMEC experiments, it links moesin to Rock1/MLC and NF-κB signaling while showing that moesin silencing reduces inflammatory and permeability responses.

• SNS-032: A CDK9-Centered Assay Strategy

  2026-09-14

  SNS-032 (BMS-387032) is a selective CDK2, CDK7, and CDK9 inhibitor whose strongest biochemical activity is against CDK9. This article develops an assay-centered framework linking RNA polymerase II phosphorylation, cancer pharmacology, and carefully bounded interpretation of emerging SARS-CoV-2 host-factor research.

• SGI-1027 Induces Apoptosis in Huh7 Cells

  2026-09-14

  The 2018 reference study examined how the non-nucleoside DNA methyltransferase inhibitor SGI-1027 affects Huh7 hepatocellular carcinoma cells. Its main contribution was linking reduced viability to apoptosis-associated changes in Bcl-2 and Bax, while finding no significant cell-cycle redistribution after treatment.

• Phosphorylated NPY1R in Intracranial Aneurysm

  2026-09-13

  The reference study identifies phosphorylated NPY1R as a mechanistic link between vascular smooth muscle cell phenotypic transition, inflammatory signaling, macrophage polarization, and intracranial aneurysm progression. By combining patient tissue analysis, a hypertensive elastase-induced mouse model, molecular assays, pharmacological intervention, and macrophage depletion, the work provides a framework for testing NPY1R-centered mechanisms in aneurysm biology.

• Wnt agonist 1: Wnt/GPX4 Assay Workflows

  2026-09-12

  Wnt agonist 1 (BML-284) provides a controllable way to activate canonical Wnt signaling in reporter, differentiation, and cancer-resistance models. This guide translates the Wnt/NR2F2/GPX4 findings from lung cancer brain metastasis research into practical assay designs, dose planning, and troubleshooting steps.

• Cimetidine in BBB Transport and Cancer Assays

  2026-09-11

  Cimetidine supports two complementary research workflows: H2 receptor biology in gastrointestinal cancer models and controlled permeability testing in surrogate blood-brain barrier systems. This guide translates the latest LLC-PK1-MDR1 findings into practical assay design, stock preparation, transport calculations, and troubleshooting decisions.

• Z-YVAD-FMK: Caspase-1 Inhibitor Workflow

  2026-09-11

  Z-YVAD-FMK is a cell-permeable, irreversible caspase-1 inhibitor for separating inflammasome-driven pyroptosis from apoptosis and other forms of cell death. This workflow combines practical dosing, orthogonal readouts, and species-aware interpretation for cancer research, inflammatory models, and gasdermin studies.

• PA-824: From Nitro-Reduction to TB Regimens

  2026-09-10

  A mechanistic and translational guide to using PA-824 as a tuberculosis research compound, with practical assay parameters and a regimen-design perspective informed by terminal oxidase biology.

• EdU Cell Proliferation Kit: From Signal to Mechanism

  2026-09-10

  The EdU Cell Proliferation Kit (TMB) converts DNA synthesis into a quantitative colorimetric readout for mechanistic cell proliferation studies. This guide explains how to use the assay to connect ARL4C-associated synoviocyte biology with S-phase measurement, pharmacodynamic drug evaluation, and genotoxicity testing.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-09

  Brumatti, Sheridan, and Martin describe an integrated workflow for bacterial expression, nickel-affinity purification, FITC labeling, and application of recombinant annexin V. The method provides a practical way to detect phosphatidylserine exposure by flow cytometry or fluorescence microscopy while clarifying why this signal should be interpreted alongside membrane-integrity measurements.

• Bicinchoninic Acid Assay (BCA) Kit Guide

  2026-09-09

  The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit, SKU K4102, supports low-concentration total protein measurement in dilute biochemical samples, cell lysates, and many detergent-containing preparations. It is intended for scientific research and sample-normalization workflows, not diagnostic, clinical, or medical testing.

• DiscoveryProbe Protease Inhibitor Library Workflow

  2026-09-08

  Build a mechanism-first protease inhibition workflow that moves from automated screening to orthogonal validation. The DiscoveryProbe™ Protease Inhibitor Library combines broad chemical coverage with pre-dissolved compounds for biochemical, cellular, and high-content assay development.

• C. albicans EVs Suppress Hyphae via Nrg1

  2026-09-08

  This study shows that accumulated Candida albicans extracellular vesicles suppress hyphal development by increasing NRG1 expression through SKO1-associated regulation. The same pathway reduced fungal burden and improved survival in a mouse candidemia model, linking EV-mediated morphogenesis control with systemic virulence.

• GSK3 Inhibition and Intracellular M. tuberculosis

  2026-09-07

  The reference study identifies host glycogen synthase kinase 3 as a controllable determinant of intracellular Mycobacterium tuberculosis growth. By combining pharmacological screening, CRISPR and RNAi perturbation, macrophage models, and phosphoproteomics, it provides a mechanistic rationale for GSK3-directed host-directed therapy rather than relying only on direct-acting antibiotics.

7922 records 1/529 page Next 12345 下5页 Last page